Anagram Therapeutics's $250M: A Big Biotech Bet Amid AI's Spotlight
Anagram Therapeutics raised $250M in May 2026, one of the largest biotech rounds of the period, proving life-sciences capital is alive alongside AI.
The Blog
A statically generated blog example with news, tutorials, resources and other interesting content related to AstroWind
Astranis's $455M: Small GEO Satellites for Affordable Connectivity
Astranis raised $455M in May 2026 to scale its small geostationary satellites, bringing dedicated connectivity to underserved regions and customers.
Astrocade's $56M: Sequoia and Sea Bet on AI-Generated Games
Astrocade raised $56M across a Sequoia-led Series B and a Sea-led Series A in May 2026, building an AI platform for creating games.
Blitzy's $200M at $1.4B: Autonomous Software Development Scales
Blitzy raised $200M at a $1.4B valuation in May 2026, led by Northzone, as autonomous software-development platforms attract serious capital.
DeepInfra's $107M Series B: Cheaper, Faster Model Inference at Scale
DeepInfra raised $107M Series B in May 2026 to scale low-cost, high-throughput AI inference infrastructure for developers and enterprises.
Panthalassa's $140M: Peter Thiel Bets on Ocean-Powered AI Compute
Panthalassa raised $140M Series B in May 2026, led by Peter Thiel, to power AI inference with ocean waves — a novel answer to AI's energy crunch.